DE1095463B - Process for the production of a perorally effective preparation for the prophylactic and curative treatment of radiation insults or other radiation damage - Google Patents
Process for the production of a perorally effective preparation for the prophylactic and curative treatment of radiation insults or other radiation damageInfo
- Publication number
- DE1095463B DE1095463B DEP18645A DEP0018645A DE1095463B DE 1095463 B DE1095463 B DE 1095463B DE P18645 A DEP18645 A DE P18645A DE P0018645 A DEP0018645 A DE P0018645A DE 1095463 B DE1095463 B DE 1095463B
- Authority
- DE
- Germany
- Prior art keywords
- radiation
- prophylactic
- perorally
- insults
- production
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 5
- 230000005855 radiation Effects 0.000 title description 11
- 238000002360 preparation method Methods 0.000 title description 5
- 230000000069 prophylactic effect Effects 0.000 title description 5
- 238000009109 curative therapy Methods 0.000 title description 4
- 238000011321 prophylaxis Methods 0.000 title description 4
- 238000004519 manufacturing process Methods 0.000 title description 3
- 150000003839 salts Chemical class 0.000 claims description 4
- 229910052779 Neodymium Inorganic materials 0.000 claims description 2
- 229910052777 Praseodymium Inorganic materials 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- 229910052746 lanthanum Inorganic materials 0.000 claims description 2
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 claims description 2
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 claims description 2
- PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical compound [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 claims description 2
- 150000003841 chloride salts Chemical class 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229910052684 Cerium Inorganic materials 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 2
- VYLVYHXQOHJDJL-UHFFFAOYSA-K cerium trichloride Chemical compound Cl[Ce](Cl)Cl VYLVYHXQOHJDJL-UHFFFAOYSA-K 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Verfahren zur Herstellung eines peroral wirksamen Präparates zur prophylaktischen und kurativen Behandlung von Strahleninsulten oder anderen Strahlungsschäden Man hat bereits zahlreiche Versuche durchgeführt, um die Wirkung von schädlichen Strahlen, wie Röntgenstrahlen oder radioaktiver Strahlen, bei biologischen Objekten zu beseitigen oder solchen Wirkungen vorzubeugen. Patt und Tyree (Science, 110, S.213, 1949) haben z. B. zur Behandlung von Röntgenschäden bei gesamtbestrahlten Ratten intravenös Cysteingaben verabfolgt; venvendet wurden unter anderem 100teige Cysteinlösungen. Lösungen dieser Art besitzen jedoch, wenn man sie 24 Stunden vor oder 24 Stunden nach der Bestrahlung injiziert, keine ausreichende Schutzwirkung. Process for the production of a perorally effective preparation for prophylactic and curative treatment of radiation insults or other radiation damage Numerous attempts have already been made to reduce the effects of harmful substances Radiation, such as X-rays or radioactive rays, on biological objects to eliminate or prevent such effects. Patt and Tyree (Science, 110, 213, 1949) have z. B. for the treatment of X-ray damage in total irradiated Rats given intravenous cysts; 100 doughs were used, among other things Cysteine solutions. Solutions of this kind, however, have if you have them 24 hours before or injected 24 hours after irradiation, insufficient protection.
Appliziert man sie im Verlauf einer Stunde vor der Bestrahlung intravenös, so ist der Erfolg nur in beschränktem Umfang wahrnehmbar.If it is administered intravenously over the course of an hour before the irradiation, so the success is only perceptible to a limited extent.
Barron und Mitarbeiter (Proc. Soc. exper. Biol. a. Barron et al. (Proc. Soc. Exper. Biol. A.
Med., 73, S. 18, und 73, S. 198, 1950) stellten weiter fest, daß Enzyme mit Sulfydrylgruppen durch Röntgenbestrahlung oxydiert und zerstört werden, wobei die Oxydationswirkung durch Zufuhr reduzierender Substanzen, wie Cystein, in gewissem Umfang aufgehoben werden kann. Toxische Produkte (Tetanustoxin) als Sekundärfolge der Bestrahlung konnten nach Ephrati und Evans (Biochem. J., 42, S. 383, 1948) durch verschiedeneAminosäuren sowie Katalase inaktiviert werden.Med., 73, p. 18, and 73, p. 198, 1950) further found that Enzymes with sulfydryl groups are oxidized and destroyed by X-ray irradiation, wherein the oxidizing effect by supplying reducing substances, such as cysteine, to a certain extent Scope can be canceled. Toxic products (tetanus toxin) as a secondary consequence according to Ephrati and Evans (Biochem. J., 42, p. 383, 1948) various amino acids as well as catalase are inactivated.
Insgesamt wurde jedoch bei den bisher bekanntgewordenen Verfahren festgestellt, daß die Anwendung von Cystein und anderen Aminosäuren nur eine vergleichsweise geringe Wirkung hat, insbesondere bleiben orale Verabreichungen ohne Wirkung.Overall, however, was in the previously known procedures found that the use of cysteine and other amino acids is only comparative has little effect, in particular oral administration has no effect.
Aus den Arbeiten und Untersuchungsreihen von R. Rugh und S. C. Wang (Proc. Soc. exp. Biol. Med., 83, S. 411 bis 414, 1953; - C, 1955, S.5115) ist zwar bekannt, daß Mäuse nach intraperitonealer Injektion mit einer Lösung von 3 mg P-Mercaptoäthylamin, mit 700 bzw. sogar 800 r bestrahlt, eine Überlebensrate von 67 bis 58°lo besitzen, dem ist jedoch entgegenzuhalten, daß das erfindungsgemäß hergestellte Präparat nicht intraperitoneal injiziert zu werden braucht, sondern peroral wirksam ist und darüber hinaus nicht nur eine prophylaktische, sondern auch eine kurative Wirksamkeit aufweist. From the work and research series by R. Rugh and S. C. Wang (Proc. Soc. Exp. Biol. Med., 83, pp. 411 to 414, 1953; - C, 1955, p. 5115) is indeed known that mice after intraperitoneal injection with a solution of 3 mg of P-mercaptoethylamine, irradiated with 700 or even 800 r, have a survival rate of 67 to 58 ° lo, However, it must be countered that the preparation produced according to the invention does not needs to be injected intraperitoneally, but is effective orally and above has not only a prophylactic, but also a curative effect.
Die Differenz zwischen 800 und 600 r (Eigenversuche) kann dabei außer Betracht bleiben, da die Letaldosis nachweislich schon bei 600 r liegt und jede darüberliegende Strahlendosierung in der Schädigung ja nicht höher liegen kann. The difference between 800 and 600 r (own tests) can also be Remain considered, since the lethal dose has been proven to be 600 r and every overlying radiation dosage in the damage cannot be higher.
Zweck der Erfindung ist deshalb die Schaffung eines oral wirksamen Präparates zur prophylaktischen und kurativen Behandlung von biologischen Objekten gegenüber Strahleninsulten und anderen Strahlenschädigungen. The purpose of the invention is therefore to create an orally effective one Preparation for the prophylactic and curative treatment of biological objects against radiation insults and other radiation damage.
Gemäß der Erfindung werden S-haltige Aminosäuren wie l-Cystin und Methionin in wäßriger Lösung und in Gegenwart von Natriumcitrat als Komplexbildner mit Salzen dreiwertiger seltener Erden umgesetzt. According to the invention, S-containing amino acids such as l-cystine and Methionine in aqueous solution and in the presence of sodium citrate as a complexing agent implemented with salts of trivalent rare earths.
Es kann dabei von Produkten ausgegangen werden, die in bekannter Weise durch fraktionierte Destillation von Estern erhalten werden, die durch Veresterung von bei der Eiweiß- oder Peptidhydrolyse erhaltenen Aminosäuren nach Emil Fischer gewonnen worden sind. It can be assumed from products that are in well-known Way by fractional distillation of esters obtained by esterification of amino acids obtained from protein or peptide hydrolysis according to Emil Fischer have been won.
Als Salze der dreiwertigen seltenen Erden kommen die Halogenide, insbesondere Chloride des Cers, Lanthans, Neodyms oder Praseodyms in Betracht. The halides come as salts of the trivalent rare earths, in particular chlorides of cerium, lanthanum, neodymium or praseodymium are considered.
Die Erfindung wird nachstehend an Hand einiger Beispiele näher erläutert. The invention is explained in more detail below with the aid of a few examples.
Beispiel 1 Keratin wird in üblicher Weise gereinigt und mit verdünnter Säure, z. B. Salzsäure, hydrolysiert. Die erhaltenen Aminosäuren werden nach üblicher Aufarbeitung aus dem Hydrolysat gewonnen, in Alkohol suspendiert und nach Emil Fischer mit Chlorwasserstoff verestert. Example 1 Keratin is cleaned in the usual way and diluted with Acid, e.g. B. hydrochloric acid, hydrolyzed. The amino acids obtained are according to the usual Work-up obtained from the hydrolyzate, suspended in alcohol and according to Emil Fischer Esterified with hydrogen chloride.
Durch Destillation wurden die wasserlöslichen Ester abgetrennt.The water-soluble esters were separated off by distillation.
Von diesen Estern wurde eine l-cystinreiche Fraktion ausgewählt und 24,03 g dieser Fraktion zusammen mit 49,2 g Cerchlorid in 500 g 1lio n-Salzsäure unter Erwärmen auf etwa 600 C unter Rühren gelöst. Die Lösung hatte einen pE-Wert von 3,2. Zu dieser Lösung wurden 69,4 g Natriumcitrat in 500 g Wasser unter ständigem Umrühren langsam hinzugefügt, wobei der pn-Wert auf 4,8 stieg. A fraction rich in l-cystine was selected from these esters and 24.03 g of this fraction together with 49.2 g of cerium chloride in 500 g of 1lion hydrochloric acid dissolved by heating to about 600 ° C. with stirring. The solution had a pE value of 3.2. To this solution were 69.4 g of sodium citrate in 500 g of water with constant Stir slowly added, the pn increasing to 4.8.
Es bildet sich eine komplexe cerhaltige Verbindung in Form eines weißen Schlammes, der mit 800loigem Äthylalkohol ausgewaschen, abgenutscht und schonend, z. B. bei 500 C, getrocknet wurde. A complex cerium-containing compound is formed in the form of a white sludge that is washed out with 800 ml of ethyl alcohol, sucked off and gently, z. B. at 500 C, was dried.
Die Ausbeute betrug etwa 78;2 g. Das Molekulargewicht der erhaltenen kristallinen Masse war 894,4, und der Schmelzpunkt betrug 123,50 C (unter Zersetzung). The yield was about 78.2 g. The molecular weight of the obtained crystalline mass was 894.4 and the melting point was 123.50 C (with decomposition).
Fünf Teilmengen von je 0,1 g der komplexen Verbindung wurden Mäusen durch eine Schlundsonde 4 Stunden vor einer Bestrahlung oral verabreicht. Die Bestrahlung erfolgte mit 600 r in Form einer Gesamtbestrahlung. Five aliquots of 0.1 g each of the complex compound were given to mice administered orally by gavage 4 hours prior to irradiation. The irradiation took place with 600 r in the form of a total irradiation.
Die bestrahlten Mäuse zeigten keine erkennbaren Schädigungen durch die Bestrahlung; ihr Haarpelz war normal, Blutungen traten nicht auf. The irradiated mice showed no noticeable damage the irradiation; her hair was normal and there was no bleeding.
In gleicher Weise mit 600 r bestrahlte Mäuse, denen jedoch keine komplexe Verbindung einverleibt worden war, zeigten schon kurze Zeit nach der Bestrahlung erhebliche Veränderungen; sie verloren ihre Haare, und es traten Blutungen aus den Leibesöffnungen auf. Der überwiegende Teil der Mäuse (über 66°lo) verendeten innerhalb der ersten 10 Tage nach der Bestrahlung; die übrigen zeigten starke Abmagerung und gingen innerhalb einer Zeit von etwa 3112 Wochen ein. Mice irradiated in the same way with 600 r, but none complex compound had been incorporated, showed a short time after the irradiation significant changes; they lost their hair and there was bleeding from them Body openings. The majority of the mice (over 66 ° lo) died within the first 10 days after irradiation; the rest showed severe emaciation and were received within approximately 3,112 weeks.
Eine weitere Gruppe von Mäusen wurde mit 600 r gesamtbestrahlt und innerhalb einer Zeit von etwa 4 Stunden nach der Bestrahlung mit oralen Verabreichungen von fünf Teilmengen von je 0,1 g der hergestellten Komplexverbindungen behandelt. Bei diesen Tieren waren praktisch keine Strahlenschädigungen festzustellen. Nach 10 Tagen lebten von den bestrahlten und nachträglich behandelten Mäusen über 66ovo, dieselben Mäuse lebten auch noch nach 3112 Wochen. Die Mäuse wurden zu Kontrolluntersuchungen alsdann ge- tötet, sie wiesen keine Organveränderungen oder -schädigungen auf. Another group of mice was total irradiated with 600 r and within about 4 hours after irradiation with oral administrations treated by five portions of 0.1 g each of the complex compounds produced. Practically no radiation damage was found in these animals. To For 10 days, the irradiated and post-treated mice lived over 66ovo, the same mice were still alive after 3112 weeks. The mice became control studies then kills, they showed no organ changes or damage.
Beispiel 2 149,2 g eines durch Caseinhydrolyse und anschließende Veresterung nach Emil Fischer gewonnenen Methionins wurden in 0,5 1 Wasser zusammen mit 24,6 g Cerchlorid unter Rühren bei etwa 600 C gelöst und die Lösung langsam mit 34,7 g Natriumcitrat in 0,5 1 Wasser unter ständigem Umrühren versetzt. Es bildet sich eine komplexe Verbindung in Form einer weißen kristallinen Masse, die mit Äther ausgewaschen und bei 500 C getrocknet wurde. Die Ausbeute betrug etwa 44,6 g. Das Molekulargewicht des Produktes war 565,9, und der Schmelzpunkt lag bei 117,30 C (unter Zersetzung). Example 2 149.2 g of a casein hydrolysis and subsequent Methionine obtained by esterification according to Emil Fischer were combined in 0.5 1 of water dissolved with 24.6 g of cerium chloride with stirring at about 600 C and the solution slowly mixed with 34.7 g of sodium citrate in 0.5 1 of water with constant stirring. It educates a complex compound in the form of a white crystalline mass made with ether was washed out and dried at 500 ° C. The yield was about 44.6 g. That The molecular weight of the product was 565.9 and the melting point was 117.30 ° C (with decomposition).
Die Produkte haben ähnliche physiologische und kurative Wirkung wie die Produkte gemäß Beispiel 1. The products have similar physiological and curative effects as the products according to example 1.
PATENTANSPROCKE: 1. Verfahren zur Herstellung eines peroral wirksamen Präparates zur prophylaktischen und kurativen Behandlung von Strahleninsulten oder anderen Strahlungsschäden, dadurch gekennzeichnet, daß man l-Cystin oder Methionin mit Salzen dreiwertiger seltener Erden in Gegenwart von Natriumcitrat als Komplexbildner umsetzt. PATENTANSPROCKE: 1. Process for the production of a perorally effective one Preparation for the prophylactic and curative treatment of radiation insults or other radiation damage, characterized in that one l-cystine or methionine with salts of trivalent rare earths in the presence of sodium citrate as a complexing agent implements.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP18645A DE1095463B (en) | 1957-05-29 | 1957-05-29 | Process for the production of a perorally effective preparation for the prophylactic and curative treatment of radiation insults or other radiation damage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP18645A DE1095463B (en) | 1957-05-29 | 1957-05-29 | Process for the production of a perorally effective preparation for the prophylactic and curative treatment of radiation insults or other radiation damage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1095463B true DE1095463B (en) | 1960-12-22 |
Family
ID=7367112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DEP18645A Pending DE1095463B (en) | 1957-05-29 | 1957-05-29 | Process for the production of a perorally effective preparation for the prophylactic and curative treatment of radiation insults or other radiation damage |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE1095463B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0138262A3 (en) * | 1983-09-26 | 1987-04-22 | Schreuder J C P Chem Adviesb | Composition for treatment of skin affections and its application |
| EP0245669A3 (en) * | 1986-05-14 | 1989-03-29 | Georg L. Prof. Dr. Floersheim | Pharmaceutical preparation for preventing damage to living cells by free radicals, or for increasing the efficacy of organic sulphur compounds, and process for increasing the life span of isolated organs |
-
1957
- 1957-05-29 DE DEP18645A patent/DE1095463B/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| None * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0138262A3 (en) * | 1983-09-26 | 1987-04-22 | Schreuder J C P Chem Adviesb | Composition for treatment of skin affections and its application |
| EP0245669A3 (en) * | 1986-05-14 | 1989-03-29 | Georg L. Prof. Dr. Floersheim | Pharmaceutical preparation for preventing damage to living cells by free radicals, or for increasing the efficacy of organic sulphur compounds, and process for increasing the life span of isolated organs |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2727150C2 (en) | Preparation that increases the pH value in the oral cavity | |
| DE2226668B2 (en) | Orally administered antihypertensive agent | |
| DE2610540C2 (en) | Use of an injectable vaccine containing OEP as an active ingredient for the prevention of mink pneumonitis caused by Pseudomonas aeruginosa | |
| DE69511448T2 (en) | Use of phosphoric acid diester compounds to suppress cancer metastases in the liver | |
| DE3854121T2 (en) | MEDICINAL COMPOSITIONS FOR TREATING PSORIASIS. | |
| DE2823346A1 (en) | ANTIVIRIAL AGENT AND METHOD OF USING THE SAME IN VIRUS INFECTION | |
| DE1095463B (en) | Process for the production of a perorally effective preparation for the prophylactic and curative treatment of radiation insults or other radiation damage | |
| DE2947646A1 (en) | SUBSTANCE WITH INTERFERON INDUCING ACTIVITY AND METHOD FOR THEIR PRODUCTION | |
| DE2753312A1 (en) | HETEROPOLYANIONAL COMPOUNDS, THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THEM | |
| Stöckl et al. | Synthesen und Reaktionen von 1, 2-Didesoxy-Hexopyrano-[2, 1-d]-Oxazolinen und-Oxazoliniumsalzen1, 2 | |
| EP0162007A1 (en) | Stable and durable insulin preparation for Acne vulgaris treatment | |
| DE2126533A1 (en) | Process for the production of pharmaceutical preparations | |
| DE3533494A1 (en) | Aerosol use of pentamidine (p,p'-(pentamethylenedioxy)-dibenzamidine bis( beta -hydroxyethanesulphonate)) for the treatment of the pneumonia caused by Pneumocystis carinii | |
| DE2610426C2 (en) | Use of a vaccine containing OEP as an active ingredient for combating mink pneumonitis caused by Pseudomonas aeruginosa | |
| DE3027056A1 (en) | PHARMACEUTICAL APPROACH TO USE AS PROTECTION AGAINST ACUTE LUNG OEDEM, ANAPHYLACTIC SHOCK AND OTHERS TYPES OF SHOCK AND HYPERFIBRINOLYSIS | |
| DE2036935B2 (en) | DIISONICOTINIC ACID HYDRAZIDE METHANE SULPHONATE OF D (+) 2,2 '- (AETHYLENEDIIMINO) -DI-L- BUTANOLS, METHOD FOR PRODUCING THE SAME AND MEDICINAL PRODUCTS CONTAINING THIS COMPOUND | |
| DE2136067C3 (en) | 3-fluoro-D-alanine, 3-fluoro-D-alanine-2-d, their salts and medicinal products containing these compounds | |
| DE2835878A1 (en) | OLIGOSACCHARIDE WITH GLUCOCORTICOID-RELATED ENZYME INDUCTION-ENHANCING EFFECT, PROCESS FOR ITS MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THIS COMPOUND | |
| DE2041831C3 (en) | Alpha-Amino-beta- (N-Benzylthiocarbamoyl) -thiopropionic acid, process for their preparation, and pharmaceuticals containing them | |
| DE2221281C3 (en) | Pharmaceutical preparations with anti-inflammatory and analgesic effects | |
| DE2609147A1 (en) | PROPIONIC ACID SALT BASED AMINO ACIDS | |
| DE69004051T2 (en) | Use of a polypeptide with gamma interferon activity for the manufacture of pharmaceutical compositions for the treatment of primitive pleural cancer. | |
| DE1543792C (en) | Monophosphoric acid esters of 2.2 biphenols and processes for their manufacture | |
| DE820788C (en) | Process for the production of a yeast liver preparation | |
| DE2932968C2 (en) |